Value questions surface after development choices are fixed.
Payer, HTA, comparator, endpoint, population, outcomes, and economic evidence needs are often discovered after the relevant studies and analyses have already been designed.
HEOR & market access intelligence
Carry evidence from development into value demonstration.
StromaOS connects evidence generation planning, health economics, outcomes research, real-world evidence, value dossiers, payer questions, HTA response, local adaptation, and market learning in one governed execution environment.
Connected value evidence
Governed economic models
Controlled local adaptation
Traceable payer response
The market access operating problem
Evidence is generated by function, but value must be demonstrated as one argument.
Market access and HEOR teams must combine clinical, epidemiological, economic, real-world, patient, utilization, and competitive evidence across markets. That work is frequently initiated late, adapted repeatedly, and managed through disconnected models, documents, vendors, and local processes.
Economic and outcomes models lose their operating context.
Inputs, assumptions, scenarios, utility values, resource use, comparators, validation, review, and market adaptations are spread across files and vendor workflows.
Each market rebuilds the value story.
Global evidence is adapted repeatedly without clear boundaries around what is approved, what may change locally, what requires review, and what evidence supports each claim.
Payer questions do not become organizational memory.
Questions, objections, evidence gaps, analyses, responses, commitments, outcomes, and market learning are often retained in local documents rather than reused globally.
How the solution works
Value evidence becomes one governed planning-to-response chain.
StromaOS coordinates evidence needs, methods, models, real-world analyses, claims, dossiers, local adaptation, payer and HTA response, commitments, and learning in one execution model.
STEP 01
Define the access question
Population, comparator, outcome, value claim, evidence gap, market requirement, payer objection, or HTA need.
STEP 02
Plan the evidence
Clinical, economic, epidemiological, real-world, patient, utilization, and market-specific evidence requirements.
STEP 03
Generate and validate
Models, analyses, cohorts, assumptions, scenarios, uncertainty, validation, review, and quality gates.
STEP 04
Assemble the value argument
Claims, evidence, model outputs, limitations, approved content, dossiers, and local adaptation boundaries.
STEP 05
Engage and respond
Payer and HTA questions, objections, analyses, commitments, negotiations, approvals, and follow-up.
STEP 06
Preserve and learn
Inputs, methods, versions, assumptions, decisions, responses, outcomes, commitments, and market learning.
Value evidence control
Every value claim remains connected to its methods, assumptions, evidence, and market boundary.
StromaOS preserves the full chain behind economic and access evidence: data inputs, cohort definitions, comparators, model structure, assumptions, utilities, resource use, scenarios, uncertainty, validation, reviewer decisions, and local adaptations.
Real-world analyses start from an approved cohort package, so the population a payer questions is the population your evidence team reviewed and approved.
Global teams can enable local execution without losing control of the evidence or approved argument.
Model a value evidence workflow
Model assumptions, sensitivity and the approval that accepted them travel together. A payer challenge lands against a record, not a rebuild.
Governance throughout value evidence
AI can accelerate analysis and response without inheriting methodological or market authority.
StromaOS separates data preparation, analysis, modeling, interpretation, claim formation, local adaptation, drafting, review, approval, negotiation, and release.
Explore the Governance Spine01
Method governance
Models, assumptions, cohorts, comparators, utilities, resource use, scenarios, validation, uncertainty, and reviewer acceptance remain part of the record.
02
Claim governance
Every value statement remains linked to approved evidence, model outputs, limitations, confidence, audience, jurisdiction, permitted use, owner, and review state.
03
Local adaptation control
Policy defines which global evidence elements may change locally, which require re-analysis, which require review, and which remain fixed.
04
Payer and HTA response authority
Drafting, scientific review, economic review, market review, approval, submission, negotiation, and commitment remain separate permissions.
05
Evidence Data Trace
Data, methods, models, prompts, assumptions, versions, reviews, decisions, claims, responses, commitments, and outcomes remain reconstructable.
Start with one evidence gap, economic model, dossier workflow, or payer response bottleneck.
Connect the evidence sources and specialist systems already in use. Define the method, assumptions, review, local adaptation boundaries, claim standard, and approval authority. Then run the work as one governed value evidence operation.